| SYMP 1. |
Crimean- Congo hemorrhagic fever: Eurasian perspective
(O. Ergönül, TR) |
| SYMP 2. |
Present situation of Gram positive infections management in Spain: Pitfalls and Success
(J.J. Picazo, ES – Spanish Society of Chemotherapy) |
| SYMP 3. |
Infective endocarditic & bloodstream infections
(C. Naber, DE-ISC Working Group on Endocarditis and Bloodstream) |
| SYMP 4. |
Avian influenza
(H. Eraksoy, TR) |
| SYMP 5. |
Control of permeability of MDR Gram negative pathogens to antibiotics: The role of porins and MDR efflux pumps
(L. Amaral, Portuguese FESCI Group) |
| SYMP 6. |
MRSA both in hospital and community: Basic Science
(G. Donelli,IT) |
| SYMP 7. |
Update on the prophylaxis and treatment of infections in leukemia patients
(J. Martens, EORTC-IDG) |
| SYMP 8. |
Risk infections and bioterrorism
(K. Metodiev, BG – Bulgarian Society of Chemotherapy) |
| SYMP 9. |
Control of multi-drug resistant gram negative bacterial infections: multidrug-resistant bacteria
(C. Büke, TR) |
| SYMP 10. |
MRSA both in hospital and community: Clinical Science
(S. Sakarya,TR) |
| SYMP 11. |
Infections in thalassemic patients
(G. L. Petrikkos, CY- Cyprus Society of Chemotherapy) |
| SYMP 12. |
Brucellosis
(G. Pappas, GR - Institute for Continuing Medical Education of Ioannina; N. Tülek, TR) |
| SYMP 13. |
Patient safety and infection control
(E. Akalın, TR) |
| SYMP 14. |
Hepatitis vaccines
(O. Ş. Yenen, TR) |
| SYMP 15. |
Emerging fungal infections in Europe and the Mediterranean area
(J. Meiss, ECMM) |
| SYMP 16. |
Chemotherapy for tropical diseases
(V. Krcmery, SK - Slovak Society of Chemotherapy) |
| SYMP 17. |
PK-PD of new antimicrobial drugs
(F. Scaglione, IT- Italian Society of Chemotherapy) |
| SYMP 18. |
Metallobetalactamases a local problem or a global threat?
(G.L. Daikos, GR- Hellenic Society of Infectious Disease) |
| SYMP 19. |
Nosocomial fungal infections
(H.Akalın, TR ) |
| SYMP 20. |
Tropical medicine for the European physician
(L. Amaral, PT - Portuguese FESCI Group ) |
| SYMP 21. |
New possibilities for reversal multi-drug resistance
(İ. Yalçın, ISN/COST B16) |
| SYMP 22. |
Infections in the ICU
(H. Giamarellou, GR – Hellenic Society of Chemotherapy) |
| SYMP 23. |
Treatment and prophylaxis in invasive fungal infections
(M. Akova,TR) |
| SYMP 24. |
Infection control and antibiotic resistance in Middle East and Africa
(A. Shibl,- MENF – Arab Society of Chemotherapy, Microbiology & Infectious Diseases) |
| SYMP 25. |
Papillomavirus vaccines
(S. Badur, TR) |
| SYMP 26. |
Treatment of HCV infection: standards and new approaches
(Y. Çakaloğlu,TR) |
| SYMP 27. |
Nosocomial and catheter associated UTI
(K. Naber, DE – ESIU ) |
| SYMP 28. |
New resistance genes and microorganisms
(G. Russo, MSC) |
| SYMP 29. |
Collateral effects of anti- infective drugs – relevance for medical practice
(M. Nechifor, RO - Romanian Society for the Study of Chemotherapeutics) |
| SYMP 30. |
Antibiotic Policy in CEE
(V. Krčméry,M. Čižman, Slovak and Slovenian Societies of Chemotherapy) |
| SYMP 31. |
Neisseria meningitidis: Can we overcome?
(O.Öncül, TR) |
| SYMP 32. |
Sepsis: 2008
(H. Giamarellou, GR – Hellenic Society of Chemotherapy) |
| SYMP 33. |
Nosocomial Infections in Europe
(H. Giamarellou, GR- FESCI) |
| SYMP 34. |
Update on prophylaxis and treatment of Aspergillosis
(L.Pagano IT – FIMUA; G.L. Petrikkos - Cyprus Society of Chemotherapy and
Infectious Diseases)
|